Foundation News

In March, the GBS/CIDP Foundation International hosted our 2013 Advocacy Capitol Hill Day. We were joined by patient advocates and their family members from throughout the United States, from Maryland to Hawaii.

This article is written by Ed Gdula, the director of advocacy for the GBS-CIDP Foundation. It discusses IVIG access and its importance to those with rare neurological disorders, including GBS and CIDP. Read full article.

Read more about Nobuhiro Yuki’s study to understand the pathogenesis of GBS in “Guillain-Barre Syndrome and anti-ganglioside antibodies: a clinician-scientist’s journey.”

CSL Behring reports that data presented from the Privigen Impact on Mobility and Autonomy (PRIMA) trial at the Peripheral Nerve Society Inflammatory Neuropathy Consortium Meeting in Rotterdam, Netherlands, suggests that treatment with Privigen®, an intravenous immunoglobulin (IVIg), may lead to improvement in function in CIDP patients. Click here to learn more.

Baxter International Inc. announces that the U.S. Food and Drug Administration has approved the first immunoglobulin treatment for Multifocal Motor Neuropathy patients in the United States. Click here to learn more.

The Journal of Neurology, Neurosurgery and Psychiatry published an article for GBS patients and families on who is most likely to improve after treatment for Guillain-Barré Syndrome. Read the full study or the lay summary.

Now@NEJM The New England Journal of Medicine posts Clinical Pearls, Morning Report Questions, and free access to an article on the current understanding, diagnosis, and management of GBS. Read the blog now

By Dennis Jackman, Senior Vice President, Public Affairs, CSL Behring People with rare and serious medical disorders encounter a host of unique challenges–from obtaining a correct diagnosis, to identifying an appropriate course of treatment and gaining affordable access to the care they need. They and their families, caretakers and health care providers face a constant struggle to identify…

In late July of 2011, Reuters published an article on the Arizona Department of Health Services reporting of a cluster of 24 cases of GBS in Yuma County. It is located in far western Arizona and neighboring San Luis Rio Colorado, in Mexico’s northern Sonora state. Even though an earlier article on msnbc.com had reported…

Ellen Schecter, an award-winning writer takes us through a time when she felt her life was shattered by this painful disease, and then shares how she was able to forge a new life filled with personal discovery and success. Neurologist and Johns Hopkins expert Dr. David Cornblath also sheds light on this mysterious disorder and…

The American Academy of Neurology recently published new guidelines, “Intravenous Immunoglobulin in the Treatment of Neuromuscular Disorders” on the efficacy of IVIg treatments in GBS, CIDP, MMN, and other neuromuscular disorder patients.